Gastroenterology
Volume 123, Issue 3 , Pages 689-699, September 2002

Selected loss of tolerance evidenced by Crohn's disease–associated immune responses to auto- and microbial antigens☆☆

  • Carol J. Landers

      Affiliations

    • Cedars–Sinai Medical Center Inflammatory Bowel Disease Center, Los Angeles, California
  • ,
  • Offer Cohavy

      Affiliations

    • Cedars–Sinai Medical Center Inflammatory Bowel Disease Center, Los Angeles, California
  • ,
  • Rajeev Misra

      Affiliations

    • Department of Microbiology, Arizona State University, Tempe, Arizona
  • ,
  • Huiying Yang

      Affiliations

    • Cedars–Sinai Medical Center Division of Medical Genetics, Los Angeles, California
  • ,
  • Ying–Chao Lin

      Affiliations

    • Cedars–Sinai Medical Center Division of Medical Genetics, Los Angeles, California
  • ,
  • Jonathan Braun

      Affiliations

    • University of California–Los Angeles School of Medicine, Department of Pathology, Los Angeles, California
  • ,
  • Stephan R. Targan

      Affiliations

    • Cedars–Sinai Medical Center Inflammatory Bowel Disease Center, Los Angeles, California

Received 22 January 2001; accepted 16 May 2002.

Abstract 

Background & Aims: Previous studies in Crohn's disease suggest global loss of tolerance with sonicated bacteria preparations containing hundreds of antigens. Monoassociation studies show that a solitary bacterium can induce colitis in one animal model, whereas another is responsible in other models. Among patients with Crohn's disease, serum responses have been documented to microbial and autoantigens (antibodies to the Escherichia coli outer-membrane porin C and the Pseudomonas fluorescens-associated sequence I2, antisaccharomyces cerevisiae antibody (ASCA), and perinuclear antineutrophil cytoplasmic antibodies). Our aim was to determine whether there are heterogeneous responses to these specific antigens. Methods: Sera from 330 Crohn's patients were analyzed. Immunoglobulin A enzyme-linked immunosorbent assays to ASCA, outer-membrane porin C, or I2 and immunoglobulin G enzyme-linked immunosorbent assay to ASCA and ANCA determined the presence and level of antibodies. Perinuclear antineutrophil cytoplasmic antibodies were determined by immunofluorescence. Results: ASCA was detected in 56% of patients; 55% were seroreactive to outer-membrane porin C, 50% were seroreactive to I2, and 23% were perinuclear antineutrophil cytoplasmic antibody positive. Eighty-five percent responded to at least 1 antigen; only 4% responded to all 4. Among microbial antigens, 78% responded to at least 1, and 57% were double positive, but only 26% responded to all 3. The level of response was stable over time and with change in disease activity. Among patients with the same qualitative antigen-response profiles, quantitative response differed. Cluster analysis of these antibody responses yielded 4 groups: ASCA, outer-membrane porin C/I2, perinuclear antineutrophil cytoplasmic antibodies, or no/low response. Conclusions: Rather than global loss of tolerance, there seem to be patient subsets with differing responses to selected microbial and autoantigens.

GASTROENTEROLOGY 2002;123:689-699

Abbreviations:  ASCA , antisaccharomyces cerevisiae antibody, BSA , bovine serum albumin, CSMC , Cedars–Sinai Medical Center, ELISA , enzyme-linked immunosorbent assay, GST , glutathione S-transferase, IL , interleukin, OmpC , outer-membrane porin C, pANCA , perinuclear antineutrophil cytoplasmic antibody, SDS , sodium dodecyl sulfate

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Address requests for reprints to: Stephan R. Targan, M.D., Director, Division of Gastroenterology, and Inflammatory Bowel Disease Center, 8700 Beverly Boulevard, Suite D4063, Los Angeles, California 90048. e-mail: targans@cshs.org; fax: (310) 423-0224.

☆☆ Supported by United States Public Health Service/National Institutes of Health grant PO 1 DK46763.

PII: S0016-5085(02)00159-2

Gastroenterology
Volume 123, Issue 3 , Pages 689-699, September 2002